Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia

References

• Koeppen AH. Friedreich’s ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci. 2011;303(1–2):1–12.
   PubMed Web of Science ®Google Scholar
• Pandolfo M. Friedreich ataxia. Handb Clin Neurol. 2012;103:275–294.
   PubMedGoogle Scholar
• Pandolfo M. Friedreich ataxia: the clinical picture. J Neurol. 2009;256(S1):3–8.
   PubMedGoogle Scholar
• Lynch DR, Schadt K, Kichula E, et al. Friedreich Ataxia: multidisciplinary clinical care. J Multidiscip Healthc. 2021;14:1645–1658.
   PubMed Web of Science ®Google Scholar
• Cossee M, Durr A, Schmitt M, et al. Friedreich’s ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol. 1999;45(2):200–206.
   PubMed Web of Science ®Google Scholar
• McDaniel DO, Keats B, Vedanarayanan VV, et al. Sequence variation in GAA repeat expansions may cause differential phenotype display in Friedreich’s ataxia. Mov Disord. 2001;16(6):1153–1158.
   PubMed Web of Science ®Google Scholar
• Bidichandani SI, Ashizawa T, Patel PI. Atypical Friedreich ataxia caused by compound heterozygosity for a novel missense mutation and the GAA triplet-repeat expansion. Am J Hum Genet. 1997;60(5):1251–1256.
   PubMed Web of Science ®Google Scholar
• Harding IH, Lynch DR, Koeppen AH, et al. Central nervous system therapeutic targets in Friedreich ataxia. Hum Gene Ther. 2020;31(23–24):1226–1236.
   PubMed Web of Science ®Google Scholar
• Martelli A, Puccio H. Dysregulation of cellular iron metabolism in Friedreich ataxia: from primary iron-sulfur cluster deficit to mitochondrial iron accumulation. Front Pharmacol. 2014;5:130.
   PubMed Web of Science ®Google Scholar
• Rötig A, de Lonlay P, Chretien D, et al. Aconitase and mitochondrial iron–sulphur protein deficiency in Friedreich ataxia. Nat Genet. 1997;17(2):215–217.
   PubMed Web of Science ®Google Scholar
• Musco G, Stier G, Kolmerer B, et al. Towards a structural understanding of Friedreich’s ataxia: the solution structure of frataxin. Structure. 2000;8(7):695–707.
   PubMed Web of Science ®Google Scholar
• Delatycki MB, Camakaris J, Brooks H, et al. Direct evidence that mitochondrial iron accumulation occurs in Friedreich ataxia. Ann Neurol. 1999;45(5):673–675.
   PubMed Web of Science ®Google Scholar
• Dürr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with friedreich’s ataxia. N Engl J Med. 1996;335(16):1169–1175.
   PubMed Web of Science ®Google Scholar
• Monrós E, Moltó MD, Martínez F, et al. Phenotype correlation and intergenerational dynamics of the Friedreich ataxia GAA trinucleotide repeat. Am J Hum Genet. 1997;61(1):101–110.
   PubMed Web of Science ®Google Scholar
• Schulz JB, Dehmer T, Schols L, et al. Oxidative stress in patients with Friedreich ataxia. Neurology. 2000;55(11):1719–1721.
   PubMed Web of Science ®Google Scholar
• Patel M, Isaacs CJ, Seyer L, et al. Progression of Friedreich ataxia: quantitative characterization over 5 years. Ann Clin Transl Neurol. 2016;3(9):684–694.
   PubMed Web of Science ®Google Scholar
• Reetz K, Dogan I, Costa AS, et al. Biological and clinical characteristics of the European Friedreich’s Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurol. 2015;14(2):174–182.
   PubMed Web of Science ®Google Scholar
• Tsou AY, Paulsen EK, Lagedrost SJ, et al. Mortality in Friedreich Ataxia. J Neurol Sci. 2011;307(1–2):46–49.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Regner SR, Schadt KA, et al. Management and therapy for cardiomyopathy in Friedreich’s ataxia. Expert Rev Cardiovasc Ther. 2012;10(6):767–777.
   PubMedGoogle Scholar
• Koeppen AH, Ramirez RL, Becker AB, et al. The pathogenesis of cardiomyopathy in Friedreich ataxia. PLoS One. 2015;10(3):e0116396–e0116396.
   PubMed Web of Science ®Google Scholar
• Dedobbeleer C, Rai M, Donal E, et al. Normal left ventricular ejection fraction and mass but subclinical myocardial dysfunction in patients with Friedreich’s ataxia. Eur Heart J Cardiovasc Imaging. 2011;13(4):346–352.
   PubMed Web of Science ®Google Scholar
• Payne RM, Wagner GR, Maria BL. Cardiomyopathy in Friedreich ataxia: clinical findings and research. J Child Neurol. 2012 September 04ed;27(9):1179–1186.
   PubMed Web of Science ®Google Scholar
• McCormick A, Shinnick J, Schadt K, et al. Cardiac transplantation in Friedreich Ataxia: extended follow-up. J Neurol Sci. 2017;375:471–473.
   PubMed Web of Science ®Google Scholar
• Sedlak TL, Chandavimol M, Straatman L. Cardiac transplantation: a temporary solution for Friedreich’s ataxia-induced dilated cardiomyopathy. J Heart Lung Transplant. 2004;23(11):1304–1306.
   PubMed Web of Science ®Google Scholar
• Ivak P, Zumrová A, Netuka I. Friedreich’s ataxia and advanced heart failure: an ethical conundrum in decision-making. J Heart Lung Transplant. 2016;35(9):1144–1145.
   PubMed Web of Science ®Google Scholar
• Mejia E, Lynch A, Hearle P, et al. Ectopic burden via holter monitors in Friedreich ataxia. Pediatr Neurol. 2021 Jan 23ed;117:29–33.
   PubMed Web of Science ®Google Scholar
• Rummey C, Flynn JM, Corben LA, et al. Scoliosis in Friedreich’s ataxia: longitudinal characterization in a large heterogeneous cohort. Ann Clin Transl Neurol. 2021 May 05ed;8(6):1239–1250.
   PubMed Web of Science ®Google Scholar
• Tsirikos AI, Smith G. Scoliosis in patients with Friedreich’s ataxia. J Bone Joint Surg Br Vol. 2012;94-B(5):684–689.
   Google Scholar
• Tamaroff J, DeDio A, Wade K, et al. Friedreich’s Ataxia related Diabetes: epidemiology and management practices. Diabetes Res Clin Pract. 2022 March 14ed;186:109828.
   PubMed Web of Science ®Google Scholar
• Azzi A-S, Cosentino C, Kibanda J, et al. OGTT is recommended for glucose homeostasis assessments in Friedreich ataxia. Ann Clin Transl Neurol. 2018;6(1):161–166.
   PubMed Web of Science ®Google Scholar
• McCormick A, Farmer J, Perlman S, et al. Impact of diabetes in the Friedreich ataxia clinical outcome measures study. Ann Clin Transl Neurol. 2017;4(9):622–631.
   PubMed Web of Science ®Google Scholar
• Pappa A, Häusler MG, Veigel A, et al. Diabetes mellitus in Friedreich Ataxia: a case series of 19 patients from the German-Austrian diabetes mellitus registry. Diabetes Res Clin Pract. 2018;141:229–236.
   PubMed Web of Science ®Google Scholar
• Chakraborty PP, Ray S, Bhattacharjee R, et al. First presentation of diabetes as diabetic ketoacidosis in a case of friedreich’s ataxia. Clin Diabetes. 2015;33(2):84–86.
   PubMedGoogle Scholar
• Seyer LA, Galetta K, Wilson J, et al. Analysis of the visual system in Friedreich ataxia. J Neurol. 2013;260(9):2362–2369.
   PubMed Web of Science ®Google Scholar
• Rojas P, de Hoz R, Cadena M, et al. Neuro-ophthalmological findings in friedreich’s ataxia. J Pers Med. 2021;11(8):708.
   PubMed Web of Science ®Google Scholar
• Bogdanova-Mihaylova P, Plapp HM, Chen H, et al. Longitudinal assessment using optical coherence tomography in patients with friedreich’s ataxia. Tomography. 2021;7(4):915–931.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Willi SM, Wilson RB, et al. A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial. Mov Disord. 2012;27(8):1026–1033.
   PubMed Web of Science ®Google Scholar
• Pandolfo M, Hausmann L. Deferiprone for the treatment of Friedreich’s ataxia. J Neurochem. 2013;126(Suppl 1):142–146.
   PubMed Web of Science ®Google Scholar
• Abeti R, Jasoliya M, Al-Mahdawi S, et al. A drug combination rescues frataxin-dependent neural and cardiac pathophysiology in FA models. Front Mol Biosci. 2022;9:830650.
   PubMed Web of Science ®Google Scholar
• Di Prospero NA, Baker A, Jeffries N, et al. Neurological effects of high-dose idebenone in patients with Friedreich’s ataxia: a randomised, placebo-controlled trial. Lancet Neurol. 2007;6(10):878–886.
   PubMed Web of Science ®Google Scholar
• Kearney M, Orrell RW, Fahey M, et al. Pharmacological treatments for Friedreich ataxia. Cochrane Database Syst Rev. 2016;2016(8):CD007791.
   PubMedGoogle Scholar
• Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch Neurol. 2010;67(8):941–947.
   PubMed Web of Science ®Google Scholar
• Wang H, Norton J, Xu L, et al. Results of a randomized double-blind study evaluating luvadaxistat in adults with Friedreich ataxia. Ann Clin Transl Neurol. 2021;8(6):1343–1352.
   PubMed Web of Science ®Google Scholar
• Keita M, McIntyre K, Rodden LN, et al. Friedreich ataxia: clinical features and new developments. Neurodegener Dis Manag. 2022;12(5):267–283.
   PubMed Web of Science ®Google Scholar
• Cook A, Giunti P. Friedreich’s ataxia: clinical features, pathogenesis and management. Br Med Bull. 2017;124(1):19–30.
   PubMed Web of Science ®Google Scholar
• Reetz K, Hilgers R-D, Isfort S, et al. Protocol of a randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich ataxia (NICOFA). Neurol Res Pract. 2019;1(1):33.
   PubMedGoogle Scholar
• Kahn-Kirby AH, Amagata A, Maeder CI, et al. Targeting ferroptosis: a novel therapeutic strategy for the treatment of mitochondrial disease-related epilepsy. PLoS One. 2019;14(3):e0214250–e0214250.
   PubMed Web of Science ®Google Scholar
• Murase K, Lee L, Ma J, et al. Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects. Eur J Clin Pharmacol. 2022;78(11):1823–1831.
   PubMed Web of Science ®Google Scholar
• Chicco AJ, Sparagna GC. Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am J Physiol Cell Physiol. 2007;292(1):C33–C44.
   PubMed Web of Science ®Google Scholar
• PTC Therapeutics. A randomized, parallel-arm, double-blind, placebo-controlled study with open-label extension to assess the efficacy and safety of vatiquinone for the treatment of Friedreich ataxia (MOVE-FA) [Internet]. clinicaltrials.gov; 2022 [cited 2022 Nov 7]. Report No.: NCT04577352. Available from: https://clinicaltrials.gov/ct2/show/NCT04577352.
   Google Scholar
• Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029–2050.
   PubMed Web of Science ®Google Scholar
• Liu Y, Cai J, Shen J, et al. SS-31 efficacy in a mouse model of Friedreich ataxia by upregulation of frataxin expression. Hum Mol Genet. 2021;31(2):176–188.
   PubMed Web of Science ®Google Scholar
• Johnson J, Mercado-Ayón E, Clark E, et al. Drp1-dependent peptide reverse mitochondrial fragmentation, a homeostatic response in Friedreich ataxia. Pharmacol Res Perspect. 2021;9(3):e00755–e00755.
   PubMed Web of Science ®Google Scholar
• Zhao H, Li H, Hao S, et al. Peptide SS-31 upregulates frataxin expression and improves the quality of mitochondria: implications in the treatment of Friedreich ataxia. Sci Rep. 2017;7(1):9840.
   PubMedGoogle Scholar
• Rodríguez-Pascau L, Britti E, Calap-Quintana P, et al. PPAR gamma agonist leriglitazone improves frataxin-loss impairments in cellular and animal models of Friedreich Ataxia. Neurobiol Dis. 2021;148:105162.
   PubMed Web of Science ®Google Scholar
• eMascaró. Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxia [Internet]. 2022 [cited 2022 Nov 8]. Available from: https://www.minoryx.com/media/minoryx%E2%80%99s_clinical_candidate_leriglitazone_shows_clinical_benefit_in_a_proof_of_concept_phase_2_study_in_friedreichs_ataxia/.
   Google Scholar
• Pandolfo M, Reetz K, Darling A, et al. Efficacy and safety of leriglitazone in patients with Friedreich ataxia. Neurol Genet. 2022;8(6):e200034.
   PubMedGoogle Scholar
• Chiang S, Kalinowski DS, Dharmasivam M, et al. The potential of the novel NAD+ supplementing agent, SNH6, as a therapeutic strategy for the treatment of Friedreich’s ataxia. Pharmacol Res. 2020;155:104680.
   PubMed Web of Science ®Google Scholar
• Libri V, Yandim C, Athanasopoulos S, et al. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich’s ataxia: an exploratory, open-label, dose-escalation study. Lancet. 2014;384(9942):504–513.
   PubMed Web of Science ®Google Scholar
• Martin AS, Abraham DM, Hershberger KA, et al. Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich’s ataxia cardiomyopathy model. JCI Insight. 2017;2(14):e93885.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Fischbeck KH. Nicotinamide in Friedreich’s ataxia: useful or not? Lancet. 2014;384(9942):474–475.
   PubMed Web of Science ®Google Scholar
• Sahdeo S, Scott BD, McMackin MZ, et al. Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich’s ataxia. Hum Mol Genet. 2014;23(25):6848–6862.
   PubMed Web of Science ®Google Scholar
• Shan Y, Schoenfeld RA, Hayashi G, et al. Frataxin deficiency leads to defects in expression of antioxidants and Nrf2 expression in dorsal root ganglia of the Friedreich’s ataxia YG8R mouse model. Antioxid Redox Signal. 2013;19(13):1481–1493.
   PubMed Web of Science ®Google Scholar
• Jasoliya M, Sacca F, Sahdeo S, et al. Dimethyl fumarate dosing in humans increases frataxin expression: a potential therapy for Friedreich’s Ataxia. PLoS One. 2019;14(6):e0217776.
   PubMed Web of Science ®Google Scholar
• Erwin GS, Grieshop MP, Ali A, et al. Synthetic transcription elongation factors license transcription across repressive chromatin. Science. 2017 Nov 30ed;358(6370):1617–1622.
   PubMed Web of Science ®Google Scholar
• Design Therapeutics – Our Approach [Internet]. 2022 [cited 2022 Nov 8]. Available from: https://www.designtx.com/our-approach/.
   Google Scholar
• Lexeo Therapeutics. A phase 1/2 study of the safety and efficacy of LX2006 gene therapy in participants with cardiomyopathy associated with friedreich’s ataxia [Internet]. clinicaltrials.gov; 2022 [cited 2022 Nov 7]. Report No.: NCT05445323. Available from: https://clinicaltrials.gov/ct2/show/NCT05445323.
   Google Scholar
• Vyas PM, Tomamichel WJ, Pride PM, et al. A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich’s ataxia mouse model. Hum Mol Genet. 2012;21(6):1230–1247.
   PubMed Web of Science ®Google Scholar
• International Congress for Ataxia Research [Internet]. 2022 [cited 2022 Nov 8]. Available from: https://ataxiacongress.org/program.htm.
   Google Scholar
• Lynch D Efficacy of omaveloxolone in patients with friedreich’s ataxia: update of the delayed-start study [Internet]. MDA Clinical & Scientific Conference 2023. [ cited 2022 Nov 9]. Available from: https://www.mdaconference.org/abstract-library/efficacy-of-omaveloxolone-in-patients-with-friedreichs-ataxia-update-of-the-delayed-start-study/.
   Google Scholar
• Larimar Therapeutics, Inc. A phase 1 single ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich’s Ataxia [Internet]. clinicaltrials.gov; 2020 [cited 2022 Nov 7]. Report No.: NCT04176991. Available from: https://clinicaltrials.gov/ct2/show/NCT04176991.
   Google Scholar
• Perdomini M, Belbellaa B, Monassier L, et al. Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich’s ataxia. Nat Med. 2014;20(5):542–547.
   PubMed Web of Science ®Google Scholar
• Gérard C, Xiao X, Filali M, et al. An AAV9 coding for frataxin clearly improved the symptoms and prolonged the life of Friedreich ataxia mouse models. Mol Ther Methods Clin Dev. 2014;1:14044.
   PubMed Web of Science ®Google Scholar
• Piguet F, de Montigny C, Vaucamps N, et al. Rapid and complete reversal of sensory ataxia by gene therapy in a novel model of Friedreich ataxia. Mol Ther. 2018 May 28ed;26(8):1940–1952.
   PubMed Web of Science ®Google Scholar
• Salami CO, Jackson K, Jose C, et al. Stress-induced mouse model of the cardiac manifestations of friedreich’s ataxia corrected by AAV-mediated gene therapy. Hum Gene Ther. 2020;31(15–16):819–827.
   PubMed Web of Science ®Google Scholar
• Belbellaa B, Reutenauer L, Monassier L, et al. Correction of half the cardiomyocytes fully rescue Friedreich ataxia mitochondrial cardiomyopathy through cell-autonomous mechanisms. Hum Mol Genet. 2019;28(8):1274–1285.
   PubMed Web of Science ®Google Scholar
• Belbellaa B, Reutenauer L, Messaddeq N, et al. High levels of frataxin overexpression lead to mitochondrial and cardiac toxicity in mouse models. Mol Ther Methods Clin Dev. 2020;19:120–138.
   PubMed Web of Science ®Google Scholar
• Sivakumar A, Cherqui S. Advantages and limitations of gene therapy and gene editing for friedreich’s ataxia. Front Genome Ed. 2022;4:903139.
   PubMedGoogle Scholar
• Mazzara PG, Muggeo S, Luoni M, et al. Frataxin gene editing rescues Friedreich’s ataxia pathology in dorsal root ganglia organoid-derived sensory neurons. Nat Commun. 2020;11(1):4178.
   PubMed Web of Science ®Google Scholar
• Rocca CJ, Rainaldi JN, Sharma J, et al. CRISPR-Cas9 gene editing of hematopoietic stem cells from patients with friedreich’s ataxia. Mol Ther Methods Clin Dev. 2020;17:1026–1036.
   PubMed Web of Science ®Google Scholar
• Li J, Rozwadowska N, Clark A, et al. Excision of the expanded GAA repeats corrects cardiomyopathy phenotypes of iPSC-derived Friedreich’s ataxia cardiomyocytes. Stem Cell Res. 2019;40:101529.
   PubMed Web of Science ®Google Scholar
• Li Y, Polak U, Bhalla AD, et al. Excision of expanded GAA repeats alleviates the molecular phenotype of friedreich’s ataxia. Mol Ther. 2015;23(6):1055–1065.
   PubMed Web of Science ®Google Scholar
• Abeti R, Uzun E, Renganathan I, et al. Targeting lipid peroxidation and mitochondrial imbalance in Friedreich’s ataxia. Pharmacol Res. 2015;99:344–350.
   PubMed Web of Science ®Google Scholar
• Abeti R, Baccaro A, Esteras N, et al. Novel Nrf2-inducer prevents mitochondrial defects and oxidative stress in friedreich’s ataxia models. Front Cell Neurosci. 2018;12:188.
   PubMed Web of Science ®Google Scholar
• Kaspar JW, Niture SK, Jaiswal AK. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med. 2009;47(9):1304–1309.
   PubMed Web of Science ®Google Scholar
• Ghosh D, Levault KR, Brewer GJ. Relative importance of redox buffers GSH and NAD (P)H in age-related neurodegeneration and Alzheimer disease-like mouse neurons. Aging Cell. 2014 March 21ed;13(4):631–640.
   PubMed Web of Science ®Google Scholar
• Holmström KM, Kostov RV, Dinkova-Kostova AT. The multifaceted role of Nrf2 in mitochondrial function. Curr Opin Toxicol. 2016;1:80–91.
   PubMedGoogle Scholar
• Wu KC, Cui JY, Klaassen CD. Beneficial role of Nrf2 in regulating NADPH generation and consumption. Toxicol Sci. 2011 September 20ed;123(2):590–600.
   PubMed Web of Science ®Google Scholar
• Hayashi G, Cortopassi G, Fang D. Lymphoblast oxidative stress genes as potential biomarkers of disease severity and drug effect in friedreich’s ataxia. PLoS One. 2016;11(4):e0153574–e0153574.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Farmer J, Hauser L, et al. Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia. Ann Clin Transl Neurol. 2018;6(1):15–26.
   PubMed Web of Science ®Google Scholar
• Reisman SA, Gahir SS, Lee C-YI, et al. Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates. Drug Des Devel Ther. 2019;13:1259–1270.
   PubMed Web of Science ®Google Scholar
• Clark E, Johnson J, Dong YN, et al. Role of frataxin protein deficiency and metabolic dysfunction in Friedreich ataxia, an autosomal recessive mitochondrial disease. Neuronal Signal. 2018;2(4):NS20180060–NS20180060.
   PubMedGoogle Scholar
• Ghanekar SD, Miller WW, Meyer CJ, et al. Orphan drugs in development for the treatment of friedreich’s ataxia: focus on omaveloxolone. Degener Neurol Neuromuscul Dis. 2019;9:103–107.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Chin MP, Delatycki M, et al. Safety and efficacy of omaveloxolone in friedreich’s ataxia (moxie study): a multicentre, randomised, double-blind, placebo-controlled trial. SSRN Electron J. 2020. DOI:10.2139/ssrn.3576913.
   Google Scholar
• Lynch DR, Goldsberry A, Rummey C, et al. Direct utility of natural history data in analysis of clinical trials: propensity match-based analysis of Omaveloxolone in Friedreich ataxia using the FA-COMS dataset. 2022. DOI:10.1101/2022.08.12.22278684.
   Google Scholar
• Chiang S, Huang MLH, Richardson DR. Treatment of dilated cardiomyopathy in a mouse model of Friedreich’s ataxia using N-acetylcysteine and identification of alterations in microRNA expression that could be involved in its pathogenesis. Pharmacol Res. 2020;159:104994.
   PubMed Web of Science ®Google Scholar
• A Clinical Drug-Drug. Interaction (DDI) Study With Omaveloxolone. Case Med Res. 2019. DOI:10.31525/ct1-nct04008186.
   Google Scholar
• CYTOCHROME P450 DRUG INTERACTION TABLE - Drug Interactions [Internet]. 2022 [cited 2022 Nov 8]. Available from: https://drug-interactions.medicine.iu.edu/MainTable.aspx.
   Google Scholar
• Shinnick JE, Schadt K, Strawser C, et al. Comorbid medical conditions in Friedreich ataxia: association with inflammatory bowel disease and growth hormone deficiency. J Child Neurol. 2016;31(9):1161–1165.
   PubMed Web of Science ®Google Scholar
• Reata Pharmaceuticals Inc. Investors - News [Internet]. [ cited 2022 Nov 9]. Available from: https://www.reatapharma.com/investors/news/default.aspx.
   Google Scholar